| Term | Definition |
| Full, Partial, Inverse | Name the three types of agonist. |
| Competitive, Noncompetitive Active Site, Reversible Allosteric (Noncompetitive), Irreversible Allosteric (Noncompetitive) | Name the four types of receptor antagonists. |
| Chemical, Physiologic | Name the two types of nonreceptor antagonists (does not bind to a receptor, but still inhibits the ability of an agonist to initiate a response) |
| competitive antagonist | this type of antagonist binds REVERSIBLY to the ACTIVE site of a receptor |
| noncompetitive active site | this type of antagonist binds IRREVERSIBLY to the ACTIVE site of a receptor |
| chemical antagonist | this nonreceptor antagonist inactivates an agonist before it has the opportunity to act |
| physiologic antagonist | this nonreceptor antagonist causes a physiologic effect opposite to that induced by the agonist |
| partial agonist | a molecule that binds to a receptor at its active site but produces only a partial response, even when all of the receptors are occupied (bound) by this type of molecule |
| True | True or False: a partial agonist can reduce the response produced by a full agonist |
| potency | Competitive antagonists reduce agonist _____ . |
| efficacy | Noncompetitive antagonists reduce agonist _____ . |
| inverse agonist | this type of agonist stops the intrinsic (constitutive) activity of the free (unoccupied) receptor |
| full agonist | stabilizes DR* (where R* is the active receptor conformation) |
| partial agonist | stabilizes both DR and DR* (where R* is the active receptor conformation) |
| inverse agonist | stabilizes DR (when R* is the intrinsic receptor conformation) |
| spare receptors | This term describes when a maximal response is achieved with less than 100% drug-receptor binding. Might be explained by receptors remaining active after agonists depart, allowing multiple receptors to be activated by a single drug molecule. Also might be explained by signal amplification, allowing a few bound receptors to produce a maximal response. |